Home/Filings/4/0001654954-19-014149
4//SEC Filing

Leo Karl 4

Accession 0001654954-19-014149

CIK 0001645469other

Filed

Dec 19, 7:00 PM ET

Accepted

Dec 20, 6:32 PM ET

Size

7.6 KB

Accession

0001654954-19-014149

Insider Transaction Report

Form 4
Period: 2019-12-18
Leo Karl
10% Owner
Transactions
  • Purchase

    Common stock

    2019-12-18$8.00/sh+313.75$2,510313.75 total
  • Purchase

    Common stock

    2019-12-18$8.00/sh+156,250$1,250,000156,250 total(indirect: See Footnote 1)
Holdings
  • Common stock

    (indirect: See Footnote 2)
    3,055,394.12
Footnotes (2)
  • [F1]This is based upon the 156,250 shares of Monopar Common Stock that KWL Investments II, LLC directly owns. As a manager of KWL Investments II, LLC, Mr. Leo may be deemed to share voting and dispositive power over these 156,250 shares. Mr. Leo disclaims beneficial ownership of the 156,250 shares held by KWL Investments II, LLC, except to the extent of his pecuniary interest therein.
  • [F2]Gem Pharmaceuticals LLC ("Gem"), an Alabama limited liability company, has voting and investment power over 3,055,394.12 of the shares of common stock held by TacticGem LLC. Karl Leo is a manager of Gem and along with other managers collectively have voting control over the securities described herein. Pharma Investments LLC ("Pharma") owns a controlling share of Gem and Karl Leo owns a controlling share of Pharma, so Pharma and its controlling shareholders have indirect control over the securities described herein. The managers of Gem and the controlling shareholders of Pharma each disclaim ownership of the shares of common stock owned by Gem, except to the extent of their pecuniary interest therein.

Issuer

Monopar Therapeutics

CIK 0001645469

Entity typeother

Related Parties

1
  • filerCIK 0001727480

Filing Metadata

Form type
4
Filed
Dec 19, 7:00 PM ET
Accepted
Dec 20, 6:32 PM ET
Size
7.6 KB